15-min delayed · Sep 11, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 22 firms covering Kymera Therapeutics Inc, 19 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $100.00 to $170.00, a moderate spread. The average target of $130.29 sits 13% above the current $115.03. The rating mix has stayed broadly stable, with Buy-side ratings easing from 20 to 19 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.26 next quarter toward $-4.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 ratings
Strong Buy
Strong Buy00%
Buy1986%
Hold314%
Sell00%
Strong Sell00%
Based on 22 analysts giving stock ratings to Kymera Therapeutics Inc.
As of Sep, 19 of 22 firms rate KYMR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KYMR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.26
Range $-1.47 – $-0.99 · 18 analysts · +29% YoY
Next period, 18 analysts expect Kymera Therapeutics Inc to earn $-1.26 a share (range $-1.47 – $-0.99), versus $-0.98 a year earlier. Full-year consensus is $-3.81, growing to $-4.95 the year after.
REVENUE · NEXT QUARTER
$3.4M
Range $-1.0M – $20.0M · 18 analysts · +18% YoY
Revenue is expected to reach $3.4M (range $-1.0M – $20.0M), +17.8% year-over-year. Full-year consensus is $105.3M, rising to $44.2M next year.
Top analysts covering Kymera Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KYMR.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$155.00+34.7% to target
Overall win rate
50%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$134.00+16.5% to target
Overall win rate
46%
+ Follow
#3
Jeff Jones
Oppenheimer · Rank #247
Buy
$120.00+4.3% to target
Overall win rate
31%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$123.00+6.9% to target
Overall win rate
47%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #337
Buy
$125.00+8.7% to target
Overall win rate
29%
+ Follow
KYMR stock forecast FAQ
What is KYMR's average 12-month price target?+
The 21 analysts with a live target average $130.29 for Kymera Therapeutics Inc over the next 12 months, ranging from a $170.00 high to a $100.00 low.
Is KYMR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 22 analyst ratings, 19 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KYMR?+
The Street-high target is $170.00 (Guggenheim), and the Street-low is $100.00 (Stephens & Co.). The average of all 21 active targets is $130.29.
How many Wall Street analysts cover KYMR?+
22 analysts have an active rating on Kymera Therapeutics Inc, and 21 firms carry a live 12-month price target.
Who is the most accurate analyst covering KYMR?+
Among analysts who currently cover KYMR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $155.00 target.
What is Kymera Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.26 per share (range $-1.47 – $-0.99) across 18 analysts. Full-year EPS is projected at $-3.81, rising to $-4.95 the following year.
How much revenue is Kymera Therapeutics Inc expected to report next quarter?+
Consensus revenue is $3.4M (range $-1.0M – $20.0M). Full-year revenue is projected at $105.3M, growing to $44.2M next year.
Have analysts been upgrading or downgrading KYMR lately?+
As of Sep, 19 of 22 firms rate KYMR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KYMR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
